{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["DR4", "DR5", "apoptosis", "c-FLIP", "caspase-8", "medicinal plants", "natural products", "polyphenols", "survivin", "tumor necrosis factor related apoptosis-inducing ligand"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38068921", "DateCompleted": {"Year": "2024", "Month": "01", "Day": "12"}, "DateRevised": {"Year": "2024", "Month": "01", "Day": "12"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "11", "Day": "22"}], "Language": ["eng"], "ELocationID": ["16596", "10.3390/ijms242316596"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "24", "Issue": "23", "PubDate": {"Year": "2023", "Month": "Nov", "Day": "22"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "TRAIL-Sensitizing Effects of Flavonoids in Cancer.", "Abstract": {"AbstractText": ["Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) represents a promising anticancer agent, as it selectively induces apoptosis in transformed cells without altering the cellular machinery of healthy cells. Unfortunately, the presence of TRAIL resistance mechanisms in a variety of cancer types represents a major hurdle, thus limiting the use of TRAIL as a single agent. Accumulating studies have shown that TRAIL-mediated apoptosis can be facilitated in resistant tumors by combined treatment with antitumor agents, ranging from synthetic molecules to natural products. Among the latter, flavonoids, the most prevalent polyphenols in plants, have shown remarkable competence in improving TRAIL-driven apoptosis in resistant cell lines as well as tumor-bearing mice with minimal side effects. Here, we summarize the molecular mechanisms, such as the upregulation of death receptor (DR)4 and DR5 and downregulation of key anti-apoptotic proteins [e.g., cellular FLICE-inhibitory protein (c-FLIP), X-linked inhibitor of apoptosis protein (XIAP), survivin], underlying the TRAIL-sensitizing properties of different classes of flavonoids (e.g., flavones, flavonols, isoflavones, chalcones, prenylflavonoids). Finally, we discuss limitations, mainly related to bioavailability issues, and future perspectives regarding the clinical use of flavonoids as adjuvant agents in TRAIL-based therapies."]}, "AuthorList": [{"Identifier": ["0000-0003-0940-2252"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Inflammatory Bowel Disease Research Laboratory, Department of Biological Sciences, Institute of Biotechnology, Federal University of Catal\u00e3o (UFCAT), Catal\u00e3o 75704020, GO, Brazil."}], "LastName": "Luiz-Ferreira", "ForeName": "Anderson", "Initials": "A"}, {"Identifier": ["0000-0002-5755-3672"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Systems Medicine, University of Rome \"Tor Vergata\", 00133 Rome, Italy."}], "LastName": "Pacifico", "ForeName": "Teresa", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Inflammatory Bowel Disease Research Laboratory, Department of Biological Sciences, Institute of Biotechnology, Federal University of Catal\u00e3o (UFCAT), Catal\u00e3o 75704020, GO, Brazil."}], "LastName": "Cruz", "ForeName": "\u00c1lefe Cardoso", "Initials": "\u00c1C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Systems Medicine, University of Rome \"Tor Vergata\", 00133 Rome, Italy."}], "LastName": "Laudisi", "ForeName": "Federica", "Initials": "F"}, {"Identifier": ["0000-0003-1339-9076"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Systems Medicine, University of Rome \"Tor Vergata\", 00133 Rome, Italy."}], "LastName": "Monteleone", "ForeName": "Giovanni", "Initials": "G"}, {"Identifier": ["0000-0002-6354-2443"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Systems Medicine, University of Rome \"Tor Vergata\", 00133 Rome, Italy."}], "LastName": "Stolfi", "ForeName": "Carmine", "Initials": "C"}], "GrantList": [{"GrantID": "202010267000183", "Agency": "Funda\u00e7\u00e3o de Amaparo \u00e0 Pesquisa do Estado de Goi\u00e1s (FAPEG)", "Country": ""}, {"GrantID": "M4C2I1.3 PE6 project PE00000019 Heal Italia", "Agency": "MUR-PNRR", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Flavonoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Ligands"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, TNF-Related Apoptosis-Inducing Ligand"}, {"RegistryNumber": "0", "NameOfSubstance": "TNF-Related Apoptosis-Inducing Ligand"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Flavonoids"}, {"QualifierName": [], "DescriptorName": "Ligands"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["metabolism"], "DescriptorName": "Receptors, TNF-Related Apoptosis-Inducing Ligand"}, {"QualifierName": ["pharmacology", "metabolism"], "DescriptorName": "TNF-Related Apoptosis-Inducing Ligand"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Tumor Necrosis Factor-alpha"}], "CoiStatement": "G.M. has served as a consultant for First Wave BioPharma and as a speaker for Takeda, Abbvie, Galapagos, and Pfizer, and filed a patent related to the treatment of inflammatory bowel diseases with Smad7 antisense oligonucleotides. The other authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31\u201346. doi: 10.1158/2159-8290.CD-21-1059.", "ArticleIdList": ["10.1158/2159-8290.CD-21-1059", "35022204"]}, {"Citation": "GBD 2019 Cancer Risk Factors Collaborators The global burden of cancer attributable to risk factors, 2010\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400:563\u2013591. doi: 10.1016/S0140-6736(22)01438-6.", "ArticleIdList": ["10.1016/S0140-6736(22)01438-6", "PMC9395583", "35988567"]}, {"Citation": "Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Vasan N., Baselga J., Hyman D.M. A view on drug resistance in cancer. Nature. 2019;575:299\u2013309. doi: 10.1038/s41586-019-1730-1.", "ArticleIdList": ["10.1038/s41586-019-1730-1", "PMC8008476", "31723286"]}, {"Citation": "Peterson C., Denlinger N., Yang Y. Recent Advances and Challenges in Cancer Immunotherapy. Cancers. 2022;14:3972. doi: 10.3390/cancers14163972.", "ArticleIdList": ["10.3390/cancers14163972", "PMC9406446", "36010965"]}, {"Citation": "van den Boogaard W.M.C., Komninos D.S.J., Vermeij W.P. Chemotherapy Side-Effects: Not All DNA Damage Is Equal. Cancers. 2022;14:627. doi: 10.3390/cancers14030627.", "ArticleIdList": ["10.3390/cancers14030627", "PMC8833520", "35158895"]}, {"Citation": "Carneiro B.A., El-Deiry W.S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 2020;17:395\u2013417. doi: 10.1038/s41571-020-0341-y.", "ArticleIdList": ["10.1038/s41571-020-0341-y", "PMC8211386", "32203277"]}, {"Citation": "Kale J., Osterlund E.J., Andrews D.W. BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ. 2018;25:65\u201380. doi: 10.1038/cdd.2017.186.", "ArticleIdList": ["10.1038/cdd.2017.186", "PMC5729540", "29149100"]}, {"Citation": "Green D.R. The Death Receptor Pathway of Apoptosis. Cold Spring Harb. Perspect. Biol. 2022;14:a041053. doi: 10.1101/cshperspect.a041053.", "ArticleIdList": ["10.1101/cshperspect.a041053", "PMC8805650", "35105716"]}, {"Citation": "Green D.R. Caspase Activation and Inhibition. Cold Spring Harb. Perspect. Biol. 2022;14:a041020. doi: 10.1101/cshperspect.a041020.", "ArticleIdList": ["10.1101/cshperspect.a041020", "PMC9341465", "35914782"]}, {"Citation": "LeBlanc H.N., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66\u201375. doi: 10.1038/sj.cdd.4401187.", "ArticleIdList": ["10.1038/sj.cdd.4401187", "12655296"]}, {"Citation": "Ramamurthy V., Yamniuk A.P., Lawrence E.J., Yong W., Schneeweis L.A., Cheng L., Murdock M., Corbett M.J., Doyle M.L., Sheriff S. The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex. Pt 10Acta Crystallogr. F Struct. Biol. Commun. 2015;71:1273\u20131281. doi: 10.1107/S2053230X15016416.", "ArticleIdList": ["10.1107/S2053230X15016416", "PMC4601591", "26457518"]}, {"Citation": "Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., McLaughlin M.M., Srinivasula S.M., Livi G.P., Marshall L.A., et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 2000;275:23319\u201323325. doi: 10.1074/jbc.M910438199.", "ArticleIdList": ["10.1074/jbc.M910438199", "10770955"]}, {"Citation": "Cha S.S., Kim M.S., Choi Y.H., Sung B.J., Shin N.K., Shin H.C., Sung Y.C., Oh B.H. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity. 1999;11:253\u2013261. doi: 10.1016/S1074-7613(00)80100-4.", "ArticleIdList": ["10.1016/S1074-7613(00)80100-4", "10485660"]}, {"Citation": "Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol. 2006;26:7046\u20137055. doi: 10.1128/MCB.00520-06.", "ArticleIdList": ["10.1128/MCB.00520-06", "PMC1592888", "16980609"]}, {"Citation": "Wang Y., Liu Y., Huang Z., Chen X., Zhang B. The roles of osteoprotegerin in cancer, far beyond a bone player. Cell Death Discov. 2022;8:252. doi: 10.1038/s41420-022-01042-0.", "ArticleIdList": ["10.1038/s41420-022-01042-0", "PMC9076607", "35523775"]}, {"Citation": "Micheau O., Shirley S., Dufour F. Death receptors as targets in cancer. Br. J. Pharmacol. 2013;169:1723\u20131744. doi: 10.1111/bph.12238.", "ArticleIdList": ["10.1111/bph.12238", "PMC3753832", "23638798"]}, {"Citation": "Willms A., Schittek H., Rahn S., Sosna J., Mert U., Adam D., Trauzold A. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells. PLoS ONE. 2019;14:e0214847. doi: 10.1371/journal.pone.0214847.", "ArticleIdList": ["10.1371/journal.pone.0214847", "PMC6448923", "30947287"]}, {"Citation": "Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005;12:228\u2013237. doi: 10.1038/sj.cgt.7700792.", "ArticleIdList": ["10.1038/sj.cgt.7700792", "15550937"]}, {"Citation": "Deng D., Shah K. TRAIL of Hope Meeting Resistance in Cancer. Trends Cancer. 2020;6:989\u20131001. doi: 10.1016/j.trecan.2020.06.006.", "ArticleIdList": ["10.1016/j.trecan.2020.06.006", "PMC7688478", "32718904"]}, {"Citation": "de Miguel D., Lemke J., Anel A., Walczak H., Martinez-Lostao L. Onto better TRAILs for cancer treatment. Cell Death Differ. 2016;23:733\u2013747. doi: 10.1038/cdd.2015.174.", "ArticleIdList": ["10.1038/cdd.2015.174", "PMC4832109", "26943322"]}, {"Citation": "Araruna M.E., Serafim C., Alves Junior E., Hiruma-Lima C., Diniz M., Batista L. Intestinal Anti-Inflammatory Activity of Terpenes in Experimental Models (2010\u20132020): A Review. Molecules. 2020;25:5430. doi: 10.3390/molecules25225430.", "ArticleIdList": ["10.3390/molecules25225430", "PMC7699610", "33233487"]}, {"Citation": "Getachew S., Medhin G., Asres A., Abebe G., Ameni G. Traditional medicinal plants used in the treatment of tuberculosis in Ethiopia: A systematic review. Heliyon. 2022;8:e09478. doi: 10.1016/j.heliyon.2022.e09478.", "ArticleIdList": ["10.1016/j.heliyon.2022.e09478", "PMC9130528", "35647341"]}, {"Citation": "Li F.S., Weng J.K. Demystifying traditional herbal medicine with modern approach. Nat. Plants. 2017;3:17109. doi: 10.1038/nplants.2017.109.", "ArticleIdList": ["10.1038/nplants.2017.109", "28758992"]}, {"Citation": "Atanasov A.G., Zotchev S.B., Dirsch V.M., The International Natural Product Sciences Taskforce. Supuran C.T. Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov. 2021;20:200\u2013216. doi: 10.1038/s41573-020-00114-z.", "ArticleIdList": ["10.1038/s41573-020-00114-z", "PMC7841765", "33510482"]}, {"Citation": "Patridge E., Gareiss P., Kinch M.S., Hoyer D. An analysis of FDA-approved drugs: Natural products and their derivatives. Drug Discov. Today. 2016;21:204\u2013207. doi: 10.1016/j.drudis.2015.01.009.", "ArticleIdList": ["10.1016/j.drudis.2015.01.009", "25617672"]}, {"Citation": "Gaobotse G., Venkataraman S., Brown P.D., Masisi K., Kwape T.E., Nkwe D.O., Rantong G., Makhzoum A. The use of African medicinal plants in cancer management. Front. Pharmacol. 2023;14:1122388. doi: 10.3389/fphar.2023.1122388.", "ArticleIdList": ["10.3389/fphar.2023.1122388", "PMC9971233", "36865913"]}, {"Citation": "Xiang Y., Guo Z., Zhu P., Chen J., Huang Y. Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science. Cancer Med. 2019;8:1958\u20131975. doi: 10.1002/cam4.2108.", "ArticleIdList": ["10.1002/cam4.2108", "PMC6536969", "30945475"]}, {"Citation": "Fridlender M., Kapulnik Y., Koltai H. Plant derived substances with anti-cancer activity: From folklore to practice. Front. Plant Sci. 2015;6:799. doi: 10.3389/fpls.2015.00799.", "ArticleIdList": ["10.3389/fpls.2015.00799", "PMC4589652", "26483815"]}, {"Citation": "Panche A.N., Diwan A.D., Chandra S.R. Flavonoids: An overview. J. Nutr. Sci. 2016;5:e47. doi: 10.1017/jns.2016.41.", "ArticleIdList": ["10.1017/jns.2016.41", "PMC5465813", "28620474"]}, {"Citation": "Havsteen B.H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 2002;96:67\u2013202. doi: 10.1016/S0163-7258(02)00298-X.", "ArticleIdList": ["10.1016/S0163-7258(02)00298-X", "12453566"]}, {"Citation": "Bojic M., Males Z., Antolic A., Babic I., Tomicic M. Antithrombotic activity of flavonoids and polyphenols rich plant species. Acta Pharm. 2019;69:483\u2013495. doi: 10.2478/acph-2019-0050.", "ArticleIdList": ["10.2478/acph-2019-0050", "31639083"]}, {"Citation": "Chang H., Lei L., Zhou Y., Ye F., Zhao G. Dietary Flavonoids and the Risk of Colorectal Cancer: An Updated Meta-Analysis of Epidemiological Studies. Nutrients. 2018;10:950. doi: 10.3390/nu10070950.", "ArticleIdList": ["10.3390/nu10070950", "PMC6073812", "30041489"]}, {"Citation": "Fardoun M.M., Maaliki D., Halabi N., Iratni R., Bitto A., Baydoun E., Eid A.H. Flavonoids in adipose tissue inflammation and atherosclerosis: One arrow, two targets. Clin. Sci. 2020;134:1403\u20131432. doi: 10.1042/CS20200356.", "ArticleIdList": ["10.1042/CS20200356", "32556180"]}, {"Citation": "Fujiki H., Watanabe T., Sueoka E., Rawangkan A., Suganuma M. Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: From Early Investigations to Current Focus on Human Cancer Stem Cells. Mol. Cells. 2018;41:73\u201382.", "ArticleIdList": ["PMC5824026", "29429153"]}, {"Citation": "Maaliki D., Shaito A.A., Pintus G., El-Yazbi A., Eid A.H. Flavonoids in hypertension: A brief review of the underlying mechanisms. Curr. Opin. Pharmacol. 2019;45:57\u201365. doi: 10.1016/j.coph.2019.04.014.", "ArticleIdList": ["10.1016/j.coph.2019.04.014", "31102958"]}, {"Citation": "Kopustinskiene D.M., Jakstas V., Savickas A., Bernatoniene J. Flavonoids as Anticancer Agents. Nutrients. 2020;12:457. doi: 10.3390/nu12020457.", "ArticleIdList": ["10.3390/nu12020457", "PMC7071196", "32059369"]}, {"Citation": "Slika H., Mansour H., Wehbe N., Nasser S.A., Iratni R., Nasrallah G., Shaito A., Ghaddar T., Kobeissy F., Eid A.H. Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms. Biomed. Pharmacother. 2022;146:112442. doi: 10.1016/j.biopha.2021.112442.", "ArticleIdList": ["10.1016/j.biopha.2021.112442", "35062053"]}, {"Citation": "Rodr\u00edguez-Garc\u00eda C., S\u00e1nchez-Quesada C., Gaforio J.J. Dietary Flavonoids as Cancer Chemopreventive Agents: An Updated Review of Human Studies. Antioxidants. 2019;8:137. doi: 10.3390/antiox8050137.", "ArticleIdList": ["10.3390/antiox8050137", "PMC6562590", "31109072"]}, {"Citation": "Rossi M., Bosetti C., Negri E., Lagiou P., La Vecchia C. Flavonoids, proanthocyanidins, and cancer risk: A network of case-control studies from Italy. Nutr. Cancer. 2010;62:871\u2013877. doi: 10.1080/01635581.2010.509534.", "ArticleIdList": ["10.1080/01635581.2010.509534", "20924962"]}, {"Citation": "Chen M., Wang X., Zha D., Cai F., Zhang W., He Y., Huang Q., Zhuang H., Hua Z.C. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Sci. Rep. 2016;6:35468. doi: 10.1038/srep35468.", "ArticleIdList": ["10.1038/srep35468", "PMC5067669", "27752089"]}, {"Citation": "Voss O.H., Arango D., Tossey J.C., Villalona Calero M.A., Doseff A.I. Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis. Cell Death Dis. 2021;12:287. doi: 10.1038/s41419-021-03567-1.", "ArticleIdList": ["10.1038/s41419-021-03567-1", "PMC7969956", "33731677"]}, {"Citation": "Oishi M., Iizumi Y., Taniguchi T., Goi W., Miki T., Sakai T. Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. PLoS ONE. 2013;8:e55922. doi: 10.1371/journal.pone.0055922.", "ArticleIdList": ["10.1371/journal.pone.0055922", "PMC3576345", "23431365"]}, {"Citation": "Kim E.Y., Yu J.S., Yang M., Kim A.K. Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5. Mol. Cells. 2013;35:32\u201340. doi: 10.1007/s10059-013-2175-2.", "ArticleIdList": ["10.1007/s10059-013-2175-2", "PMC3887848", "23224239"]}, {"Citation": "Kang C.H., Molagoda I.M.N., Choi Y.H., Park C., Moon D.O., Kim G.Y. Apigenin promotes TRAIL-mediated apoptosis regardless of ROS generation. Food Chem. Toxicol. 2018;111:623\u2013630. doi: 10.1016/j.fct.2017.12.018.", "ArticleIdList": ["10.1016/j.fct.2017.12.018", "29247770"]}, {"Citation": "Yan J., Wang Q., Zheng X., Sun H., Zhou Y., Li D., Lin Y., Wang X. Luteolin enhances TNF-related apoptosis-inducing ligand\u2019s anticancer activity in a lung cancer xenograft mouse model. Biochem. Biophys. Res. Commun. 2012;417:842\u2013846. doi: 10.1016/j.bbrc.2011.12.055.", "ArticleIdList": ["10.1016/j.bbrc.2011.12.055", "22206675"]}, {"Citation": "Ou Y.C., Li J.R., Kuan Y.H., Raung S.L., Wang C.C., Hung Y.Y., Pan P.H., Lu H.C., Chen C.J. Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis. Life Sci. 2014;100:110\u2013117. doi: 10.1016/j.lfs.2014.02.002.", "ArticleIdList": ["10.1016/j.lfs.2014.02.002", "24530290"]}, {"Citation": "Nazim U.M., Park S.Y. Luteolin sensitizes human liver cancer cells to TRAIL-induced apoptosis via autophagy and JNK-mediated death receptor 5 upregulation. Int. J. Oncol. 2019;54:665\u2013672. doi: 10.3892/ijo.2018.4633.", "ArticleIdList": ["10.3892/ijo.2018.4633", "30431076"]}, {"Citation": "Wu B., Xiong J., Zhou Y., Wu Y., Song Y., Wang N., Chen L., Zhang J. Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission. Arch. Biochem. Biophys. 2020;692:108539. doi: 10.1016/j.abb.2020.108539.", "ArticleIdList": ["10.1016/j.abb.2020.108539", "32777260"]}, {"Citation": "Zhang Z., Ye T., Cai X., Yang J., Lu W., Hu C., Wang Z., Wang X., Cao P. 5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins. Evid. Based Complement. Alternat Med. 2013;2013:434709. doi: 10.1155/2013/434709.", "ArticleIdList": ["10.1155/2013/434709", "PMC3600283", "23533482"]}, {"Citation": "Yang J.F., Cao J.G., Tian L., Liu F. 5,7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells. Cancer Chemother. Pharmacol. 2012;69:195\u2013206. doi: 10.1007/s00280-011-1686-9.", "ArticleIdList": ["10.1007/s00280-011-1686-9", "21660448"]}, {"Citation": "Lirdprapamongkol K., Sakurai H., Abdelhamed S., Yokoyama S., Athikomkulchai S., Viriyaroj A., Awale S., Ruchirawat S., Svasti J., Saiki I. Chrysin overcomes TRAIL resistance of cancer cells through Mcl-1 downregulation by inhibiting STAT3 phosphorylation. Int. J. Oncol. 2013;43:329\u2013337. doi: 10.3892/ijo.2013.1926.", "ArticleIdList": ["10.3892/ijo.2013.1926", "23636231"]}, {"Citation": "Ding J., Polier G., Kohler R., Giaisi M., Krammer P.H., Li-Weber M. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J. Biol. Chem. 2012;287:641\u2013649. doi: 10.1074/jbc.M111.286526.", "ArticleIdList": ["10.1074/jbc.M111.286526", "PMC3249118", "22086925"]}, {"Citation": "Bronikowska J., Szliszka E., Kostrzewa-Suslow E., Jaworska D., Czuba Z.P., Bednarski P., Krol W. Novel Structurally Related Flavones Augment Cell Death Induced by rhsTRAIL. Int. J. Mol. Sci. 2017;18:1211. doi: 10.3390/ijms18061211.", "ArticleIdList": ["10.3390/ijms18061211", "PMC5486034", "28587286"]}, {"Citation": "Zhang L., Wang X., Wang R., Zheng X., Li N., Li H., Cao X., Zhou B., Lin Y., Yang L. Baicalin potentiates TRAIL-induced apoptosis through p38 MAPK activation and intracellular reactive oxygen species production. Mol. Med. Rep. 2017;16:8549\u20138555. doi: 10.3892/mmr.2017.7633.", "ArticleIdList": ["10.3892/mmr.2017.7633", "28983599"]}, {"Citation": "Xie R., Gao C.C., Yang X.Z., Wu S.N., Wang H.G., Zhang J.L., Yan W., Ma T.H. Combining TRAIL and liquiritin exerts synergistic effects against human gastric cancer cells and xenograft in nude mice through potentiating apoptosis and ROS generation. Biomed. Pharmacother. 2017;93:948\u2013960. doi: 10.1016/j.biopha.2017.06.095.", "ArticleIdList": ["10.1016/j.biopha.2017.06.095", "28715876"]}, {"Citation": "Xu Z.F., Sun X.K., Lan Y., Han C., Zhang Y.D., Chen G. Linarin sensitizes tumor necrosis factor-related apoptosis (TRAIL)-induced ligand-triggered apoptosis in human glioma cells and in xenograft nude mice. Biomed. Pharmacother. 2017;95:1607\u20131618. doi: 10.1016/j.biopha.2017.08.021.", "ArticleIdList": ["10.1016/j.biopha.2017.08.021", "28950661"]}, {"Citation": "Szliszka E., Helewski K.J., Mizgala E., Krol W. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Int. J. Oncol. 2011;39:771\u2013779.", "ArticleIdList": ["21743964"]}, {"Citation": "Han M.A., Lee D.H., Woo S.M., Seo B.R., Min K.J., Kim S., Park J.W., Kim S.H., Choi Y.H., Kwon T.K. Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells. Sci. Rep. 2016;6:18642. doi: 10.1038/srep18642.", "ArticleIdList": ["10.1038/srep18642", "PMC4698673", "26725939"]}, {"Citation": "Song W., Yan C.Y., Zhou Q.Q., Zhen L.L. Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK. Biomed. Pharmacother. 2017;89:845\u2013856. doi: 10.1016/j.biopha.2017.01.062.", "ArticleIdList": ["10.1016/j.biopha.2017.01.062", "28282786"]}, {"Citation": "Jacquemin G., Granci V., Gallouet A.S., Lalaoui N., Morle A., Iessi E., Morizot A., Garrido C., Guillaudeux T., Micheau O. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin\u2019s lymphoma B cells. Haematologica. 2012;97:38\u201346. doi: 10.3324/haematol.2011.046466.", "ArticleIdList": ["10.3324/haematol.2011.046466", "PMC3248929", "21933852"]}, {"Citation": "Kim J.H., Kim M.J., Choi K.C., Son J. Quercetin sensitizes pancreatic cancer cells to TRAIL-induced apoptosis through JNK-mediated cFLIP turnover. Int. J. Biochem. Cell Biol. 2016;78:327\u2013334. doi: 10.1016/j.biocel.2016.07.033.", "ArticleIdList": ["10.1016/j.biocel.2016.07.033", "27477310"]}, {"Citation": "Yi L., Zongyuan Y., Cheng G., Lingyun Z., Guilian Y., Wei G. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci. 2014;105:520\u2013527. doi: 10.1111/cas.12395.", "ArticleIdList": ["10.1111/cas.12395", "PMC4317845", "24612139"]}, {"Citation": "Manouchehri J.M., Turner K.A., Kalafatis M. TRAIL-Induced Apoptosis in TRAIL-Resistant Breast Carcinoma Through Quercetin Cotreatment. Breast Cancer. 2018;12:1178223417749855. doi: 10.1177/1178223417749855.", "ArticleIdList": ["10.1177/1178223417749855", "PMC5802616", "29434473"]}, {"Citation": "Turner K.A., Manouchehri J.M., Kalafatis M. Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin. Melanoma Res. 2018;28:277\u2013285. doi: 10.1097/CMR.0000000000000447.", "ArticleIdList": ["10.1097/CMR.0000000000000447", "PMC6039425", "29596115"]}, {"Citation": "Zhao Y., Tian B., Wang Y., Ding H. Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5. Med. Sci. Monit. 2017;23:5096\u20135105. doi: 10.12659/MSM.903552.", "ArticleIdList": ["10.12659/MSM.903552", "PMC5669221", "29070784"]}, {"Citation": "Hassanzadeh A., Naimi A., Hagh M.F., Saraei R., Marofi F., Solali S. Kaempferol Improves TRAIL-Mediated Apoptosis in Leukemia MOLT-4 Cells by the Inhibition of Anti-apoptotic Proteins and Promotion of Death Receptors Expression. Anticancer. Agents Med. Chem. 2019;19:1835\u20131845. doi: 10.2174/1871520619666190731155859.", "ArticleIdList": ["10.2174/1871520619666190731155859", "31364517"]}, {"Citation": "Tang S.Y., Zhong M.Z., Yuan G.J., Hou S.P., Yin L.L., Jiang H., Yu Z. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells. Oncol. Rep. 2013;29:474\u2013480. doi: 10.3892/or.2012.2127.", "ArticleIdList": ["10.3892/or.2012.2127", "23135489"]}, {"Citation": "Lee S.H., Kim M.J., Kim D.W., Kang C.D., Kim S.H. Amurensin G enhances the susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity of cancer stem-like cells of HCT-15 cells. Cancer Sci. 2013;104:1632\u20131639. doi: 10.1111/cas.12299.", "ArticleIdList": ["10.1111/cas.12299", "PMC7653517", "24118446"]}, {"Citation": "Arumugam S., Bandil K., Proksch P., Murugiyan K., Bharadwaj M. Effects of A. marina-Derived Isoquercitrin on TNF-Related Apoptosis-Inducing Ligand Receptor (TRAIL-R) Expression and Apoptosis Induction in Cervical Cancer Cells. Appl. Biochem. Biotechnol. 2017;182:697\u2013707. doi: 10.1007/s12010-016-2355-6.", "ArticleIdList": ["10.1007/s12010-016-2355-6", "28013431"]}, {"Citation": "Nazim U.M., Park S.Y. Genistein enhances TRAIL-induced cancer cell death via inactivation of autophagic flux. Oncol. Rep. 2015;34:2692\u20132698. doi: 10.3892/or.2015.4247.", "ArticleIdList": ["10.3892/or.2015.4247", "26352862"]}, {"Citation": "Parajuli B., Shin S.J., Kwon S.H., Cha S.D., Lee H.G., Bae I., Cho C.H. The synergistic apoptotic interaction of Indole-3-Carbinol and Genistein with TRAIL on endometrial cancer cells. J. Korean Med. Sci. 2013;28:527\u2013533. doi: 10.3346/jkms.2013.28.4.527.", "ArticleIdList": ["10.3346/jkms.2013.28.4.527", "PMC3617304", "23580227"]}, {"Citation": "Szliszka E., Czuba Z.P., Mertas A., Paradysz A., Krol W. The dietary isoflavone biochanin-A sensitizes prostate cancer cells to TRAIL-induced apoptosis. Urol. Oncol. 2013;31:331\u2013342. doi: 10.1016/j.urolonc.2011.01.019.", "ArticleIdList": ["10.1016/j.urolonc.2011.01.019", "21803611"]}, {"Citation": "Kim Y.J., Choi W.I., Ko H., So Y., Kang K.S., Kim I., Kim K., Yoon H.G., Kim T.J., Choi K.C. Neobavaisoflavone sensitizes apoptosis via the inhibition of metastasis in TRAIL-resistant human glioma U373MG cells. Life Sci. 2014;95:101\u2013107. doi: 10.1016/j.lfs.2013.10.035.", "ArticleIdList": ["10.1016/j.lfs.2013.10.035", "24231449"]}, {"Citation": "Xu Y., Gao C.C., Pan Z.G., Zhou C.W. Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells. Biochem. Biophys. Res. Commun. 2018;496:998\u20131005. doi: 10.1016/j.bbrc.2018.01.003.", "ArticleIdList": ["10.1016/j.bbrc.2018.01.003", "29305260"]}, {"Citation": "Szliszka E., Jaworska D., Ksek M., Czuba Z.P., Krol W. Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells. Int. J. Mol. Sci. 2012;13:15343\u201315359. doi: 10.3390/ijms131115343.", "ArticleIdList": ["10.3390/ijms131115343", "PMC3509645", "23203129"]}, {"Citation": "Kauntz H., Bousserouel S., Gosse F., Raul F. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells. Apoptosis. 2012;17:797\u2013809. doi: 10.1007/s10495-012-0731-4.", "ArticleIdList": ["10.1007/s10495-012-0731-4", "22555452"]}, {"Citation": "Wei R., Zhu G., Jia N., Yang W. Epigallocatechin-3-gallate Sensitizes Human 786-O Renal Cell Carcinoma Cells to TRAIL-Induced Apoptosis. Cell Biochem. Biophys. 2015;72:157\u2013164. doi: 10.1007/s12013-014-0428-0.", "ArticleIdList": ["10.1007/s12013-014-0428-0", "25539708"]}, {"Citation": "Kwon O.S., Jung J.H., Shin E.A., Park J.E., Park W.Y., Kim S.H. Epigallocatechin-3-Gallate Induces Apoptosis as a TRAIL Sensitizer via Activation of Caspase 8 and Death Receptor 5 in Human Colon Cancer Cells. Biomedicines. 2020;8:84. doi: 10.3390/biomedicines8040084.", "ArticleIdList": ["10.3390/biomedicines8040084", "PMC7235876", "32283836"]}, {"Citation": "Song T., Zhang M., Wu J., Chen F., Wang Y., Ma Y., Dai Z. Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo. Investig. New Drugs. 2020;38:1743\u20131754. doi: 10.1007/s10637-020-00979-2.", "ArticleIdList": ["10.1007/s10637-020-00979-2", "32767162"]}, {"Citation": "Han H., Xu B., Hou P., Jiang C., Liu L., Tang M., Yang X., Zhang Y., Liu Y. Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis. Cell Biochem. Biophys. 2015;72:533\u2013542. doi: 10.1007/s12013-014-0499-y.", "ArticleIdList": ["10.1007/s12013-014-0499-y", "25577511"]}, {"Citation": "Park D., Ha I.J., Park S.Y., Choi M., Lim S.L., Kim S.H., Lee J.H., Ahn K.S., Yun M., Lee S.G. Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells. J. Nat. Prod. 2016;79:317\u2013323. doi: 10.1021/acs.jnatprod.5b00919.", "ArticleIdList": ["10.1021/acs.jnatprod.5b00919", "26829656"]}, {"Citation": "Engelsgjerd S., Kunnimalaiyaan S., Kandil E., Gamblin T.C., Kunnimalaiyaan M. Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines. PLoS ONE. 2019;14:e0213776. doi: 10.1371/journal.pone.0213776.", "ArticleIdList": ["10.1371/journal.pone.0213776", "PMC6417737", "30870485"]}, {"Citation": "Minakawa T., Toume K., Arai M.A., Koyano T., Kowithayakorn T., Ishibashi M. Prenylflavonoids isolated from Artocarpus champeden with TRAIL-resistance overcoming activity. Phytochemistry. 2013;96:299\u2013304. doi: 10.1016/j.phytochem.2013.08.015.", "ArticleIdList": ["10.1016/j.phytochem.2013.08.015", "24074554"]}, {"Citation": "Toume K., Habu T., Arai M.A., Koyano T., Kowithayakorn T., Ishibashi M. Prenylated flavonoids and resveratrol derivatives isolated from Artocarpus communis with the ability to overcome TRAIL resistance. J. Nat. Prod. 2015;78:103\u2013110. doi: 10.1021/np500734t.", "ArticleIdList": ["10.1021/np500734t", "25537111"]}, {"Citation": "Zhou W., Cao A., Wang L., Wu D. Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells. Cell Biochem. Biophys. 2015;72:241\u2013249. doi: 10.1007/s12013-014-0444-0.", "ArticleIdList": ["10.1007/s12013-014-0444-0", "25524636"]}, {"Citation": "Seo O.W., Kim J.H., Lee K.S., Lee K.S., Kim J.H., Won M.H., Ha K.S., Kwon Y.G., Kim Y.M. Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-kappaB-dependent cFLIP expression in HeLa cells. Exp. Mol. Med. 2012;44:653\u2013664. doi: 10.3858/emm.2012.44.11.074.", "ArticleIdList": ["10.3858/emm.2012.44.11.074", "PMC3509182", "22932446"]}, {"Citation": "Du J., Wu J., Fu X., Tse A.K., Li T., Su T., Yu Z.L. Icariside II overcomes TRAIL resistance of melanoma cells through ROS-mediated downregulation of STAT3/cFLIP signaling. Oncotarget. 2016;7:52218\u201352229. doi: 10.18632/oncotarget.10582.", "ArticleIdList": ["10.18632/oncotarget.10582", "PMC5239546", "27418138"]}, {"Citation": "Cho H.D., Gu I.A., Won Y.S., Moon K.D., Park K.H., Seo K.I. Auriculasin sensitizes primary prostate cancer cells to TRAIL-mediated apoptosis through up-regulation of the DR5-dependent pathway. Food Chem. Toxicol. 2019;126:223\u2013232. doi: 10.1016/j.fct.2019.02.030.", "ArticleIdList": ["10.1016/j.fct.2019.02.030", "30817944"]}, {"Citation": "Kim B., Seo J.H., Lee K.Y., Park B. Icariin sensitizes human colon cancer cells to TRAIL-induced apoptosis via ERK-mediated upregulation of death receptors. Int. J. Oncol. 2020;56:821\u2013834. doi: 10.3892/ijo.2020.4970.", "ArticleIdList": ["10.3892/ijo.2020.4970", "32124960"]}, {"Citation": "Hostetler G.L., Ralston R.A., Schwartz S.J. Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity. Adv. Nutr. 2017;8:423\u2013435. doi: 10.3945/an.116.012948.", "ArticleIdList": ["10.3945/an.116.012948", "PMC5421117", "28507008"]}, {"Citation": "Salehi B., Quispe C., Chamkhi I., El Omari N., Balahbib A., Sharifi-Rad J., Bouyahya A., Akram M., Iqbal M., Docea A.O., et al. Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence. Front. Pharmacol. 2020;11:592654. doi: 10.3389/fphar.2020.592654.", "ArticleIdList": ["10.3389/fphar.2020.592654", "PMC7849684", "33536909"]}, {"Citation": "Manouchehri J.M., Kalafatis M. Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment. Anticancer. Res. 2017;37:6593\u20136599.", "ArticleIdList": ["29187434"]}, {"Citation": "Razeghian E., Suksatan W., Sulaiman Rahman H., Bokov D.O., Abdelbasset W.K., Hassanzadeh A., Marofi F., Yazdanifar M., Jarahian M. Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges. Front. Immunol. 2021;12:699746. doi: 10.3389/fimmu.2021.699746.", "ArticleIdList": ["10.3389/fimmu.2021.699746", "PMC8417882", "34489946"]}, {"Citation": "Buchsbaum D.J., Forero-Torres A., LoBuglio A.F. TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol. 2007;3:405\u2013409. doi: 10.2217/14796694.3.4.405.", "ArticleIdList": ["10.2217/14796694.3.4.405", "17661715"]}, {"Citation": "Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer. 2008;8:782\u2013798. doi: 10.1038/nrc2465.", "ArticleIdList": ["10.1038/nrc2465", "18813321"]}, {"Citation": "Snajdauf M., Havlova K., Vachtenheim J., Jr., Ozaniak A., Lischke R., Bartunkova J., Smrz D., Strizova Z. The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Front. Mol. Biosci. 2021;8:628332. doi: 10.3389/fmolb.2021.628332.", "ArticleIdList": ["10.3389/fmolb.2021.628332", "PMC8006409", "33791337"]}, {"Citation": "Laudisi F., Pacifico T., Maresca C., Luiz-Ferreira A., Antonelli S., Ortenzi A., Colantoni A., Di Grazia A., Franze E., Colella M., et al. Rafoxanide sensitizes colorectal cancer cells to TRAIL-mediated apoptosis. Biomed. Pharmacother. 2022;155:113794. doi: 10.1016/j.biopha.2022.113794.", "ArticleIdList": ["10.1016/j.biopha.2022.113794", "36271571"]}, {"Citation": "Safa A.R., Pollok K.E. Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers. 2011;3:1639\u20131671. doi: 10.3390/cancers3021639.", "ArticleIdList": ["10.3390/cancers3021639", "PMC3281420", "22348197"]}, {"Citation": "Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 2012;11:109\u2013124. doi: 10.1038/nrd3627.", "ArticleIdList": ["10.1038/nrd3627", "22293567"]}, {"Citation": "Garg H., Suri P., Gupta J.C., Talwar G.P., Dubey S. Survivin: A unique target for tumor therapy. Cancer Cell Int. 2016;16:49. doi: 10.1186/s12935-016-0326-1.", "ArticleIdList": ["10.1186/s12935-016-0326-1", "PMC4917988", "27340370"]}, {"Citation": "Tu H., Costa M. XIAP\u2019s Profile in Human Cancer. Biomolecules. 2020;10:1493. doi: 10.3390/biom10111493.", "ArticleIdList": ["10.3390/biom10111493", "PMC7692959", "33138314"]}, {"Citation": "Warren C.F.A., Wong-Brown M.W., Bowden N.A. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019;10:177. doi: 10.1038/s41419-019-1407-6.", "ArticleIdList": ["10.1038/s41419-019-1407-6", "PMC6384907", "30792387"]}, {"Citation": "Kaloni D., Diepstraten S.T., Strasser A., Kelly G.L. BCL-2 protein family: Attractive targets for cancer therapy. Apoptosis. 2023;28:20\u201338. doi: 10.1007/s10495-022-01780-7.", "ArticleIdList": ["10.1007/s10495-022-01780-7", "PMC9950219", "36342579"]}, {"Citation": "Cardoso Alves L., Corazza N., Micheau O., Krebs P. The multifaceted role of TRAIL signaling in cancer and immunity. FEBS J. 2021;288:5530\u20135554. doi: 10.1111/febs.15637.", "ArticleIdList": ["10.1111/febs.15637", "33215853"]}, {"Citation": "Bugel S.M., Bonventre J.A., Tanguay R.L. Comparative Developmental Toxicity of Flavonoids Using an Integrative Zebrafish System. Toxicol. Sci. 2016;154:55\u201368. doi: 10.1093/toxsci/kfw139.", "ArticleIdList": ["10.1093/toxsci/kfw139", "PMC5091365", "27492224"]}, {"Citation": "Galati G., O\u2019Brien P.J. Potential toxicity of flavonoids and other dietary phenolics: Significance for their chemopreventive and anticancer properties. Free Radic. Biol. Med. 2004;37:287\u2013303. doi: 10.1016/j.freeradbiomed.2004.04.034.", "ArticleIdList": ["10.1016/j.freeradbiomed.2004.04.034", "15223063"]}, {"Citation": "Skibola C.F., Smith M.T. Potential health impacts of excessive flavonoid intake. Free Radic. Biol. Med. 2000;29:375\u2013383. doi: 10.1016/S0891-5849(00)00304-X.", "ArticleIdList": ["10.1016/S0891-5849(00)00304-X", "11035267"]}, {"Citation": "Bisol A., de Campos P.S., Lamers M.L. Flavonoids as anticancer therapies: A systematic review of clinical trials. Phytother. Res. 2020;34:568\u2013582. doi: 10.1002/ptr.6551.", "ArticleIdList": ["10.1002/ptr.6551", "31752046"]}, {"Citation": "Liskova A., Samec M., Koklesova L., Brockmueller A., Zhai K., Abdellatif B., Siddiqui M., Biringer K., Kudela E., Pec M., et al. Flavonoids as an effective sensitizer for anti-cancer therapy: Insights into multi-faceted mechanisms and applicability towards individualized patient profiles. EPMA J. 2021;12:155\u2013176. doi: 10.1007/s13167-021-00242-5.", "ArticleIdList": ["10.1007/s13167-021-00242-5", "PMC8126506", "34025826"]}, {"Citation": "Farhan M., Rizvi A., Aatif M., Ahmad A. Current Understanding of Flavonoids in Cancer Therapy and Prevention. Metabolites. 2023;13:481. doi: 10.3390/metabo13040481.", "ArticleIdList": ["10.3390/metabo13040481", "PMC10142845", "37110140"]}, {"Citation": "Ferreira M., Costa D., Sousa A. Flavonoids-Based Delivery Systems towards Cancer Therapies. Bioengineering. 2022;9:197. doi: 10.3390/bioengineering9050197.", "ArticleIdList": ["10.3390/bioengineering9050197", "PMC9137930", "35621475"]}, {"Citation": "Crozier A., Del Rio D., Clifford M.N. Bioavailability of dietary flavonoids and phenolic compounds. Mol. Aspects Med. 2010;31:446\u2013467. doi: 10.1016/j.mam.2010.09.007.", "ArticleIdList": ["10.1016/j.mam.2010.09.007", "20854839"]}, {"Citation": "Manach C., Donovan J.L. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic. Res. 2004;38:771\u2013785. doi: 10.1080/10715760410001727858.", "ArticleIdList": ["10.1080/10715760410001727858", "15493450"]}, {"Citation": "Dewanjee S., Chakraborty P., Bhattacharya H., Singh S.K., Dua K., Dey A., Jha N.K. Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy. Drug Discov. Today. 2023;28:103409. doi: 10.1016/j.drudis.2022.103409.", "ArticleIdList": ["10.1016/j.drudis.2022.103409", "36265733"]}, {"Citation": "Cunha C., Daniel-da-Silva A.L., Oliveira H. Drug Delivery Systems and Flavonoids: Current Knowledge in Melanoma Treatment and Future Perspectives. Micromachines. 2022;13:1838. doi: 10.3390/mi13111838.", "ArticleIdList": ["10.3390/mi13111838", "PMC9693869", "36363859"]}, {"Citation": "Ronka S., Kowalczyk A., Baczynska D., Zolnierczyk A.K. Pluronics-Based Drug Delivery Systems for Flavonoids Anticancer Treatment. Gels. 2023;9:143. doi: 10.3390/gels9020143.", "ArticleIdList": ["10.3390/gels9020143", "PMC9957264", "36826313"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "10", "Day": "13"}, {"Year": "2023", "Month": "11", "Day": "16"}, {"Year": "2023", "Month": "11", "Day": "20"}, {"Year": "2023", "Month": "12", "Day": "17", "Hour": "9", "Minute": "44"}, {"Year": "2023", "Month": "12", "Day": "9", "Hour": "10", "Minute": "43"}, {"Year": "2023", "Month": "12", "Day": "9", "Hour": "1", "Minute": "13"}, {"Year": "2023", "Month": "11", "Day": "22"}], "PublicationStatus": "epublish", "ArticleIdList": ["38068921", "PMC10706592", "10.3390/ijms242316596", "ijms242316596"]}}], "PubmedBookArticle": []}